Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Azasetron. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A known ✓ | P46098 | 3/20 | 0.98 |
| ▸ | KCNH2 known ✓ | Q12809 | 2/20 | 0.98 |
| ▸ | HTR2A known ✓ | P28223 | 1/20 | 0.98 |
| ▸ | SLC6A4 known ✓ | P31645 | 1/20 | 0.98 |
| ▸ | HRH1 known ✓ | P35367 | 1/20 | 0.98 |
| ▸ | PDE4D known ✓ | Q08499 | 1/20 | 0.98 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.98 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Azasetron SCHEMBL1023863 | 1.00 | HTR3A (0.98) | HTR3AKCNH2HTR2ASLC6A4HRH1 | |
| Azasetron SCHEMBL19492326 | 0.99 | HTR3A (1.00) | HTR3AKCNH2HTR2ASLC6A4HRH1 | |
| Azasetron SCHEMBL29880168 | 0.99 | HTR3A (1.00) | HTR3AKCNH2HTR2ASLC6A4HRH1 | |
| Azasetron SCHEMBL13186328 | 0.99 | HTR3A (1.00) | HTR3AKCNH2HTR2ASLC6A4HRH1 | |
| Azasetron SCHEMBL19463750 | 0.99 | HTR3A (1.00) | HTR3AKCNH2HTR2ASLC6A4HRH1 | |
| Azasetron SCHEMBL17190 | 0.99 | HTR3A (1.00) | HTR3AKCNH2HTR2ASLC6A4HRH1 | |
| Azasetron SCHEMBL17191 | 0.99 | HTR3A (1.00) | HTR3AKCNH2HTR2ASLC6A4HRH1 | |
| Azasetron SCHEMBL29089146 | 0.97 | HTR3A (0.96) | HTR3AKCNH2HTR2ASLC6A4HRH1 | |
| Azasetron SCHEMBL1649657 | 0.97 | HTR3A (0.96) | HTR3AKCNH2HTR2ASLC6A4HRH1 | |
| Azasetron SCHEMBL19463074 | 0.94 | HTR3A (0.89) | HTR3AKCNH2HTR2ASLC6A4HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 539 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144776-A1 | COMBINATION THERAPY FOR A DOPAMINE AGONIST | ALTO NEUROSCIENCE, INC. (US) | 2026-05-28 | — | — | US | claimed |
| US-20240366639-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO INC (US) | 2024-11-07 | — | — | US | claimed |
| EP-4335508-A2 | (+)-AZASETRON FOR USE IN THE TREATMENT OF EAR DISORDERS | Sensorion (FR) | 2024-03-13 | — | — | EP | claimed |
| EP-3442537-B1 | (+)-AZASETRON FOR USE IN THE TREATMENT OF EAR DISORDERS | SENSORION (FR) | 2024-01-10 | — | — | EP | claimed |
| CN-112062687-B | Synthesis method of azasetron hydrochloride intermediate 3-amino-5-chloro-2-hydroxybenzoic acid methyl ester | 上海信谊万象药业股份有限公司 | 2023-11-21 | — | — | CN | claimed |
| US-20230226071-A1 | METHOD OF PREVENTING COCHLEAR DISEASE, DISORDER OR CONDITION USING (+)-AZASETRON | SENSORION (FR) | 2023-07-20 | — | — | US | claimed |
| US-11612605-B2 | (+)-azasetron for use in the treatment of ear disorders | SENSORION (FR) | 2023-03-28 | — | — | US | claimed |
| WO-2023016546-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO, INC. (US) | 2023-02-16 | — | — | WO | claimed |
| CN-112062687-A | Synthetic method of azasetron hydrochloride intermediate 3-amino-5-chloro-2-hydroxybenzoic acid methyl ester | 上海信谊万象药业股份有限公司 | 2020-12-11 | — | — | CN | claimed |
| CN-110563721-A | Preparation method of azasetron hydrochloride | 成都大学 | 2019-12-13 | — | — | CN | claimed |
| EP-2077106-A1 | W/O/W EMULSION COMPOSITION | Controlled Lipo Techs, Inc. (JP) | 2009-07-08 | — | — | EP | claimed |
| CN-100423779-C | Medicinal composition comprising active components of 5-HT 3 receptor antagonist and H2 receptor antagonist and use thereof | UNIV CHINA PHARMA (CN) | 2008-10-08 | — | — | CN | claimed |
| CN-101130080-A | Gelling agent for controlling and releasing 5-HT* acceptor antagon and method of preparing the same | UNIV SHANDONG (CN) | 2008-02-27 | — | — | CN | claimed |
| CN-101108849-A | Benzo 58743 | TOKUYAMA CORP (JP) | 2008-01-23 | — | — | CN | claimed |
| CN-1927398-A | Medicinal composition comprising active components of 5-HT 3 receptor antagonist and H2 receptor antagonist and use thereof | UNIV CHINA PHARMA (CN) | 2007-03-14 | — | — | CN | claimed |
| CN-1775215-A | Azasetron hydrochloride glucose injection formulation, and its preparing method and quality control technology | YU SHICHUN (CN) | 2006-05-24 | — | — | CN | claimed |
| CN-1552326-A | Method for stabilizing intravenous injection of azasejoin | 上海延安万象药业股份有限公司 | 2004-12-08 | — | — | CN | claimed |
| CN-1498618-A | Injection of hydrochloric 'Azasiqiong' powder and its prepn. method | 南京中西制剂研究所 | 2004-05-26 | — | — | CN | claimed |
| CN-1498619-A | Hydrochloric 'Azasiqiong' tablet and its preparing method | 南京中西制剂研究所 | 2004-05-26 | — | — | CN | claimed |
| US-6440453-B1 | MIXTURE WITH TEA TREE OIL, ETHANOL AND WATER; SIDE EFFECT REDUCTION DURING CHEMOTHERAPY FOR CANCER AND/OR TUMORS | NOVOSIS PHARMA AG (DE) | 2002-08-27 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11612605-B2 | (+)-azasetron for use in the treatment of ear disorders | SLC26A4, OTC, ENTPD5 | HTR3A 788/4885KCNH2 1724/4885HTR2A 2569/4885 |
| US-20260144776-A1 | COMBINATION THERAPY FOR A DOPAMINE AGONIST | SLC6A3, SLC6A4, HTR4 | HTR3A 4/4885KCNH2 1065/4885HTR2A 23/4885 |
| US-20240366639-A1 | HETEROCYCLIC GLP-1 AGONISTS | GLP1R, GIPR, GCGR | HTR3A 143/4885KCNH2 1020/4885HTR2A 252/4885 |
| US-20230226071-A1 | METHOD OF PREVENTING COCHLEAR DISEASE, DISORDER OR CONDITION USING (+)-AZASETRON | SLC26A4, SLC26A3, ENTPD5 | HTR3A 1344/4885KCNH2 755/4885HTR2A 3258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.